These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 9113438)

  • 1. Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective.
    Samara E; Granneman R
    Clin Pharmacokinet; 1997 Apr; 32(4):294-312. PubMed ID: 9113438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of population pharmacokinetics in drug development.
    Vozeh S; Steimer JL; Rowland M; Morselli P; Mentre F; Balant LP; Aarons L
    Clin Pharmacokinet; 1996 Feb; 30(2):81-93. PubMed ID: 8906893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche.
    Reigner BG; Williams PE; Patel IH; Steimer JL; Peck C; van Brummelen P
    Clin Pharmacokinet; 1997 Aug; 33(2):142-52. PubMed ID: 9260036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How modeling and simulation have enhanced decision making in new drug development.
    Miller R; Ewy W; Corrigan BW; Ouellet D; Hermann D; Kowalski KG; Lockwood P; Koup JR; Donevan S; El-Kattan A; Li CS; Werth JL; Feltner DE; Lalonde RL
    J Pharmacokinet Pharmacodyn; 2005 Apr; 32(2):185-97. PubMed ID: 16283534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics. A regulatory perspective.
    Sun H; Fadiran EO; Jones CD; Lesko L; Huang SM; Higgins K; Hu C; Machado S; Maldonado S; Williams R; Hossain M; Ette EI
    Clin Pharmacokinet; 1999 Jul; 37(1):41-58. PubMed ID: 10451782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated pharmacokinetics and pharmacodynamics in drug development.
    Dingemanse J; Appel-Dingemanse S
    Clin Pharmacokinet; 2007; 46(9):713-37. PubMed ID: 17713971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of pharmacokinetic-pharmacodynamic relationships in drug development].
    Bellissant E; Courcier-Duplantier S; Blin O;
    Therapie; 2002; 57(4):347-57. PubMed ID: 12422555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of modelling and simulation in Phase I drug development.
    Aarons L; Karlsson MO; Mentré F; Rombout F; Steimer JL; van Peer A;
    Eur J Pharm Sci; 2001 May; 13(2):115-22. PubMed ID: 11297895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of pharmacokinetic and pharmacodynamic studies in the discovery, development, and review of protein therapeutic agents: a conference report.
    Galluppi GR; Rogge MC; Roskos LK; Lesko LJ; Green MD; Feigal DW; Peck CC
    Clin Pharmacol Ther; 2001 Jun; 69(6):387-99. PubMed ID: 11406736
    [No Abstract]   [Full Text] [Related]  

  • 16. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How do pharmaceutical companies approach data from sexual health studies for regulatory agencies?
    Dilleen M; Haughie S
    Annu Rev Sex Res; 2005; 16():53-61. PubMed ID: 16913287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing pharmacokinetic and pharmacodynamic interactions in clinical trials of antiepileptic drugs.
    Reife RA
    Adv Neurol; 1998; 76():95-103. PubMed ID: 9408466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal blood sampling time windows for parameter estimation using a population approach: design of a phase II clinical trial.
    Chenel M; Ogungbenro K; Duval V; Laveille C; Jochemsen R; Aarons L
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):737-56. PubMed ID: 16341474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
    Falit BP
    Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.